NDAORALTABLET
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEPADIN (bepridil hydrochloride) is an oral small-molecule calcium channel blocker approved in 1990 for the treatment of chronic angina pectoris. It reduces myocardial oxygen demand and improves coronary blood flow through non-selective calcium channel antagonism. The drug is indicated for patients with stable angina who are inadequately controlled or intolerant to other antianginal agents.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting cost-containment and defensive positioning activities for the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BEPADIN offers limited growth trajectory and primarily defensive career opportunities focused on market share protection and managed decline. Roles are typically cost-constrained and focused on operational efficiency rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on BEPADIN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.